ArticleCureus2025
Patient-Derived Xenograft Mouse Model of a Rare Gynecologic Malignancy: Personalized Medicine for the Treatment of Mesonephric-Like Adenocarcinoma.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMesonephric-like adenocarcinoma (MLA) is a rare malignant tumor that mainly occurs in the uterine body and ovaries and has characteristics similar to mesonephric adenocarcinoma in the uterine cervix. Although MLA has a poor clinical prognosis, no standard treatment for MLA has been developed, mainly because of its rarity. Here, we aimed to develop a precision medicine platform for MLA using a patient-derived xenograft (PDX) mouse model.
methodsWe established an MLA PDX mouse model via orthotopic implantation of a primary uterine tumor. Whole exome sequencing of the primary MLA tumor was performed to detect the genomic characteristics. For drug testing, we generated a patient-derived explant (PDE) model using sliced PDX tumors on medium-soaked gelatin sponges exposed to drugs. As another evaluation method, we cultured MLA cells from PDX tumors via a three-dimensional culture method with each drug treatment. Furthermore, we investigated the antitumor effects of a combination of trametinib and omipalisib compared with carboplatin in MLA PDX mice in vivo.
resultsMLA PDX tumors exhibited similar histological features to the original patient tumors. Whole exome sequencing revealedpathogenic variants of
conclusionsWe established a PDX model of MLA to facilitate personalized treatment for rare tumors.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.